Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Faculty of Medicine, Heart Institute, Hadassah University Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Compr Physiol. 2023 Jun 26;13(3):4719-4765. doi: 10.1002/cphy.c220001.
Heart transplantation (HT) is one of the prodigious achievements in modern medicine and remains the cornerstone in the treatment of patients with advanced heart failure. Advances in surgical techniques, immunosuppression, organ preservation, infection control, and allograft surveillance have improved short- and long-term outcomes thereby contributing to greater clinical success of HT. However, prolonged allograft and patient survival following HT are still largely restricted by the development of late complications, including allograft rejection, infection, cardiac allograft vasculopathy (CAV), and malignancy. The introduction of mTOR inhibitors early after HT has demonstrated multiple protective effects against CAV progression, renal dysfunction, and tumorigenesis. Therefore, several HT programs increasingly use mTOR inhibitors with partial or complete withdrawal of calcineurin inhibitor (CNI) in stable HT patients to reduce complications risk and improve long-term outcomes. Furthermore, despite a substantial improvement in exercise capacity and health-related quality of life after HT as compared to advanced heart failure patients, most HT recipients remain with a 30% to 50% lower peak oxygen consumption (Vo ) than that of age-matched healthy subjects. Several factors, including alterations in central hemodynamics, HT-related complications and alterations in the musculoskeletal system, and peripheral physiological abnormalities, presumably contribute to the reduced exercise capacity following HT. Cardiac denervation and subsequent loss of sympathetic and parasympathetic regulation are responsible for various physiological alterations in the cardiovascular system, which contributes to restricted exercise tolerance. Restoration of cardiac innervation may improve exercise capacity and quality of life, but the reinnervation process is only partial even several years after HT. Multiple studies have shown that aerobic and strengthening exercise interventions improve exercise capacity by increasing maximal heart rate, chronotropic response, and peak Vo after HT. Novel exercise modalities, such as high-intensity interval training (HIT), have been proven as safe and effective for further improvement in exercise capacity, including among de novo HT recipients. Further developments have recently emerged, including donor heart preservation techniques, noninvasive CAV and rejection surveillance methods, and improvements in immunosuppressive therapies, all aiming at increasing donor availability and improving late survival after HT. © 2023 American Physiological Society. Compr Physiol 13:4719-4765, 2023.
心脏移植(HT)是现代医学的杰出成就之一,仍然是治疗晚期心力衰竭患者的基石。手术技术、免疫抑制、器官保存、感染控制和同种异体移植物监测的进步改善了短期和长期结果,从而为 HT 的更大临床成功做出了贡献。然而,HT 后移植物和患者的长期存活仍然在很大程度上受到晚期并发症的限制,包括移植物排斥、感染、心脏移植物血管病(CAV)和恶性肿瘤。HT 后早期使用 mTOR 抑制剂已被证明具有多种针对 CAV 进展、肾功能障碍和肿瘤发生的保护作用。因此,一些 HT 计划越来越多地在稳定的 HT 患者中使用 mTOR 抑制剂,部分或完全停用钙调神经磷酸酶抑制剂(CNI),以降低并发症风险并改善长期结果。此外,尽管与晚期心力衰竭患者相比,HT 后患者的运动能力和健康相关生活质量有了实质性提高,但大多数 HT 受者的峰值摄氧量(Vo )仍比年龄匹配的健康受试者低 30%至 50%。几个因素,包括中心血液动力学的改变、HT 相关并发症和肌肉骨骼系统的改变以及外周生理异常,可能导致 HT 后运动能力下降。心脏去神经支配以及随后失去交感和副交感调节是心血管系统各种生理改变的原因,这导致运动耐量受限。心脏神经再支配可能改善运动能力和生活质量,但即使在 HT 后数年,再支配过程也只是部分的。多项研究表明,有氧运动和力量训练干预可通过增加最大心率、变时反应和 HT 后的峰值 Vo 来改善运动能力。高强度间歇训练(HIT)等新型运动方式已被证明是安全有效的,可以进一步提高运动能力,包括在新接受 HT 的患者中。最近出现了一些新的进展,包括供心保存技术、非侵入性 CAV 和排斥监测方法以及免疫抑制治疗的改进,所有这些都旨在增加供体的可用性并提高 HT 后的晚期存活率。© 2023 美国生理学会。综合生理学 13:4719-4765,2023。